Abstract
Purpose :
To analyse the functional and structural outcomes for patients who were given Faricimab in both treatment naïve and suboptimal responders of nAMD and DMO .
Methods :
Single-centre retrospective analysis which evaluated the Best Corrected Visual Acuity (BCVA) , and Central Macular Thickness (CMT) during each visit of the monthly 4 loading doses of Faricimab .
Results :
1.The study analysed 129 eyes with nAMD, where 95 patients were treatment naïve and 34 patients were suboptimal responders
2.30 eyes of patients with DMO were also analysed where 19 eyes were treatment naïve and 11 eyes were suboptimal responders .
3.Mean visual acuity was 53.3 letters at baseline , which improved to 59 letters at the first and second visits , 61 letters at the 3rd visit and 60 letters at the 4th visit in nAMD patients
4.Mean visual acuity was 58.36 letters at baseline which became 57 letters at the second visit which improved to 62.41 letters at the third visit and 60.5 letters at the fourth visit in DMO patients
5. Mean central macular thickness was 393 microns at baseline , which reduced to 293 microns at the first visit , 290 microns at the second visit , 297 microns at the third visit and then 308 microns at the 4th visit in nAMD patients
6. Mean central macular thickness was 427.5 microns at baseline , which reduced to 367.75 microns at the second visit which further reduced to 336.41 microns at the third visit and then to 321.36 microns at the fourth visit in DMO patients.
Conclusions :
1.Mean gain in visual acuity was 15.05 letters from baseline in treatment naïve patients of nAMD , with central macular thickness reduction of 112.38 microns after 4 loading doses of Faricimab , with stable vision of 64 letters at baseline and at the end of 4 loading doses in patients who were suboptimal responders with a CMT reduction of 30.76 microns .
2. In treatment naïve patients of diabetic macular oedema , the mean gain in vision was 5.7 letters from baseline with reduction in central macular thickness of 142.72 microns after four loading injections of Faricimab , while a stable vision of 60 letters from the baseline was noted in suboptimal responders with reduction in CMT of 28.61 microns .
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.